Radioligand-Binding Assay Reveals Distinct Autoantibody Preferences for Type I Interferons in APS I and Myasthenia Gravis Subgroups

Abstract

Patients with autoimmune polyendocrine syndrome type I (APS I) or acquired thymoma-associated myasthenia gravis (MG) surprisingly share several common features, including defective expression of the transcription factor AIRE and autoantibodies against type I interferons. Here, we have adapted and validated the radioligand-binding assay we recently developed against 35S-Met-interferon-ω, for rapid and specific screening for autoantibodies against interferons-α2 and -α8. We then investigated their potential for diagnosis and for predicting clinical manifestations in patients with APS I and different subgroups of MG. Autoantibodies against interferons-ω, -α2, and -α8 occurred more often in patients with APS I (100%) and MG with thymoma (73%) than in late-onset MG (39%) and early-onset MG (5%). These autoantibodies showed preferences for interferon-ω in APS I and for the interferon-αs in MG, hinting at thymic aberrations in both groups. The exact profile of type I interferon antibodies may indicate MG subtype and may hint at thymoma recurrence.

DOI: 10.1007/s10875-011-9617-4

Extracted Key Phrases

4 Figures and Tables

0204060201220132014201520162017
Citations per Year

75 Citations

Semantic Scholar estimates that this publication has 75 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Hapnes2011RadioligandBindingAR, title={Radioligand-Binding Assay Reveals Distinct Autoantibody Preferences for Type I Interferons in APS I and Myasthenia Gravis Subgroups}, author={Liv Hapnes and Nick Willcox and Bergithe E. V. Oftedal and Jone Furlund Owe and Nils Erik Gilhus and Anthony Meager and Eystein Sverre Husebye and Anette Susanne B\oe Wolff}, journal={Journal of Clinical Immunology}, year={2011}, volume={32}, pages={230-237} }